Johnson & Johnson (NYSE: JNJ) announced on August 24 that the FDA has approved IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA) in adults and adolescents 12 and older who are currently or previously treated with corticosteroids, making it the first FDA-approved therapy specifically for the disease. The approval followed FDA Priority Review and is IMAAVY’s second approved use; the drug was first approved in April 2025 for generalized myasthenia gravis (gMG) in antibody-positive patients, so this expands an already-commercial product into a second rare-disease indication rather than launching an entirely new drug.

What wAIHA Is

wAIHA is a rare condition in which the immune system produces antibodies that attach to and destroy a patient’s own red blood cells, causing severe anemia, profound fatigue, and an increased risk of complications including blood clots, acute kidney failure, and infection. Citing figures from the National Organization for Rare Disorders, J&J says roughly 1 to 3 new cases occur per 100,000 people each year, with about 1 in 8,000 people living with the condition; it affects both men and women, with incidence rising after age 50. Before this approval, the only treatment options were corticosteroids and broader immunosuppressants that suppress the immune system generally rather than targeting the specific antibodies driving the disease.

How IMAAVY Works

IMAAVY works differently: it is designed to block the neonatal Fc receptor, or FcRn, which reduces circulating levels of the type of antibody (IgG) that drives wAIHA, while J&J says it preserves broader B-cell immune function based on laboratory and animal studies. The approval rests on the Phase 2/3 ENERGY trial (NCT04119050), a randomized, double-blind, placebo-controlled study that enrolled 115 adults split roughly evenly across two IMAAVY dosing schedules and placebo, with results presented at the European Hematology Association’s 2026 meeting in June.

What the Trial Showed

The trial’s primary endpoint was durable hemoglobin response, defined specifically as a hemoglobin level of at least 10 g/dL along with an increase of at least 2 g/dL from baseline sustained for 28 days without needing rescue therapy. J&J reports that roughly three times as many patients on the approved 30 mg/kg dose achieved that durable response by 24 weeks compared with placebo, a result the company says reached statistical significance. Patients on that dose also showed a mean hemoglobin increase of 1 g/dL within the first week of treatment, with a median time to initial response of about 4 weeks, compared to about 12 weeks in the placebo group. On a secondary fatigue measure (FACIT-Fatigue), IMAAVY-treated patients scored a mean of 3.5 points better than placebo at 24 weeks, with a 95% confidence interval of 0.64 to 6.39; J&J explicitly labels this and the early hemoglobin timing results as descriptive rather than confirmatory findings, since they fell outside the trial’s formally pre-specified primary statistical analysis.

Safety Profile

On safety, J&J says IMAAVY’s profile in the wAIHA trial was consistent with its established safety record in gMG, with the most common side effects occurring in 10% or more of wAIHA patients being peripheral edema (swelling), diarrhea, and fever. The drug’s full prescribing information carries warnings about infection risk, allergic and infusion-related reactions, and a pregnancy safety monitoring program, all standard for this class of immune-modulating therapy.

What the Companies and Clinicians Are Saying

Karen Jones, president of the patient advocacy group wAIHA Warriors, described the disease as involving cycles of feeling better followed by relapse, and said the approval gives patients a treatment aimed specifically at their disease for the first time; the release discloses she was not compensated for this comment. David Kuter, a hematologist at Massachusetts General Hospital who has consulted for J&J, said the trial demonstrated that targeting the disease-driving antibodies directly could change how wAIHA is treated. Both are attributed, disclosed perspectives rather than independent third-party analysis. J&J’s David M. Lee, head of the company’s Global Immunology therapeutic area, called the underserved wAIHA community’s long wait for an approved treatment a motivation for the company’s continued work in antibody-driven diseases, a characterization of the company’s strategic priorities rather than a specific data point.

What’s Next

For J&J, this approval extends the commercial runway for nipocalimab, which the company says it is also studying across a broader set of antibody-driven conditions, including other rheumatologic and rare autoantibody diseases and a maternal-fetal use aimed at limiting transfer of harmful maternal antibodies to a fetus. Nipocalimab holds a range of FDA and European designations across these programs, including Fast Track, Orphan Drug, and Breakthrough Therapy status in various indications, though most of those additional uses remain in earlier stages of development and are not part of this approval. Pricing for the wAIHA indication was not disclosed in this release, and none is estimated here.

This article covers an FDA drug approval and underlying trial data and is not investment or medical advice; patients should discuss treatment decisions with a qualified healthcare professional.

Sources

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), PRNewswire, August 24, 2026.

Editorial Disclosure

This article is based on a press release issued by Johnson & Johnson on August 24, 2026, distributed via PRNewswire. Johnson & Johnson trades on the New York Stock Exchange under the ticker JNJ. BioTech Stocks Daily was not compensated for this coverage. Efficacy figures are drawn from the Phase 2/3 ENERGY trial as reported by Johnson & Johnson; some results, including early hemoglobin response timing and the FACIT-Fatigue score difference, are described by the company as descriptive rather than statistically confirmatory findings. This article is for informational and educational purposes only, does not constitute investment advice, and is not medical advice. Consult a qualified healthcare professional for medical guidance. See our full DISCLAIMER.